Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1548 studies found for:    cancer | bevacizumab
Show Display Options
Rank Status Study
1 Active, not recruiting Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer
Condition: Breast Cancer
Interventions: Drug: bevacizumab;   Drug: no bevacizumab
2 Completed
Has Results
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: ABI-007;   Drug: Bevacizumab
3 Recruiting Fluorescence Guided Surgery in Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Bevacizumab-800CW
4 Completed Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Bevacizumab (Avastin)
5 Recruiting Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: TAS-102 and Bevacizumab
6 Completed
Has Results
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer;   Locally Advanced Breast Cancer
Interventions: Drug: Gemcitabine;   Drug: Bevacizumab
7 Completed VEGF Early Imaging for Breast Cancer
Condition: Breast Cancer
Intervention: Other: 89Zr-bevacizumab PET
8 Completed
Has Results
Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Drug: Docetaxel
9 Recruiting Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum Sensitive Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Niraparib;   Drug: Bevacizumab
10 Active, not recruiting Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab;   Other: no maintenance
11 Completed Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Bevacizumab, docetaxel, cisplatin
12 Completed Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Bevacizumab, Abraxane
13 Enrolling by invitation Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention: Drug: Bevacizumab
14 Completed First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer
Condition: Colorectal Cancer Stage II
Intervention: Drug: Bevacizumab and FOLFIRI
15 Completed
Has Results
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
Condition: Cancer
Interventions: Drug: Pemetrexed;   Drug: Bevacizumab
16 Active, not recruiting Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Drug: fulvestrant
17 Recruiting Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Maintenance:BEVACIZUMAB;   Drug: Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE
18 Terminated
Has Results
Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
Condition: Colon Cancer
Intervention: Drug: FOLFOX and bevacizumab
19 Completed VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer
Condition: Breast Cancer
Intervention: Drug: bevacizumab-IRDye800CW
20 Active, not recruiting Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
Condition: Metastatic Breast Cancer
Interventions: Drug: low-dose-bevacizumab/pemetrexed;   Drug: Treatment of physician's choice

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.